newsfilter
← Latest News
GlobeNewswire·

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

Two pivotal Phase 3 clinical trials studying soticlestat as a treatment for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) completed enrollment; Takeda anticipates topline data readout by or before September